ClinicalTrials.gg
TerminatedNCT05315479Updated Sep 13, 2023Results posted

Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery

A Phase 4 interventional study of N1539 in Post Operative Pain, sponsored by Baudax Bio. Terminated at 3 sites in United States. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Baudax Bio · Phase 4, Interventional, and Treatment

Why this study was terminated
Anjeso (N1539) NDA Withdrawn

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
2 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing meloxicam in Pain, Postoperative — 2 open to participants now, 3 under way, none of them phase 3. Meloxicam · Pain, Postoperative.

Enrollment
23rd of 24
19 · median 112
Started
2022
with 1 other
Phase 4
5 of 24
1 open now
Registered
20th of 24
by date
Lead sponsor
7 of 24
Baudax Bio

Among the 24 studies testing meloxicam in Pain, Postoperative, this one is the 23rd largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 4, and was the 20th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 24 studies testing meloxicam in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About meloxicam

Meloxicam: first FDA approval 2000 (MOBIC), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 2 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing meloxicam in Pain, Postoperative, or all of them as a file.
02

Study summary

This study is an open-label, multicenter evaluation of Safety and Pharmacokinetics of N1539 in postoperative Pediatric subjects aged 2 to \<17 years.

03

Conditions studied

  • Post Operative Pain

Browse trials for

Keywords

  • meloxicam
  • pediatric
04

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 2 to \<17 years of age before dosing on Day 1
  • Eligible for elective surgery that will be performed according to standard surgical technique under appropriate anesthesia
  • Be premenarche or have confirmed negative urine pregnancy testing before surgery on Day 1, if an adolescent female of
  • Willing and able to cooperate with all the requirements of the study; including providing appropriate /assent

Exclusion criteria

Exclusion Criteria:

  • Have a known allergy or to meloxicam, aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs), or any of N1539
  • Have a known bleeding disorder that may be worsened with the administration of an NSAID
  • Be undergoing cardiothoracic surgery
  • Has used meloxicam within 7 days before the surgical procedure on Day 1
  • Has any medical history or clinical manifestations of significant disease or any other condition that increases the risk associated with the subject's participation in the study or compromises the scientific objectives of the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    N1539

    N1539 (Meloxicam IV) 0.6 mg/kg (maximum 30 mg) Q24H

    Drug: N1539

Interventions

  • DrugN1539

    Once daily

    Also known as: Meloxicam IV

06

What researchers measure

Primary outcomes

  1. Number of Subjects Experiencing an AE

    Number of study subjects who experienced an AE

    Time frame: Through study completion, approximately 28 Days

07

Results

Posted Sep 13, 2023

Participant flow

Participant flow — Overall Study
MilestoneN1539
Started19
Completed19
Not completed0

Outcome measures

PrimaryNumber of Subjects Experiencing an AE

Number of study subjects who experienced an AE

Time frame:
Through study completion, approximately 28 Days
Reported as:
Count of participants · Participants
Number of Subjects Experiencing an AE
ParticipantsN1539
Number of Subjects Experiencing an AE3

Adverse events

Collected over 28 Days following study dosing. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
N15390/19 (0%)0/19 (0%)3/19 (15.8%)
Most frequent other events
Most frequent other events
EventN1539
Tooth infectionInfections and infestations1/19
PyrexiaGeneral disorders1/19
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/19
NauseaGastrointestinal disorders1/19

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)N1539
<=18 years19
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(years)N1539
Median16 (12 to 16)
Sex: Female, Male
Sex: Female, Male(Participants)N1539
Female9
Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)N1539
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American2
White15
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)N1539
United States19
08

Study locations

3 sites
  • Research Center
    Sheffield, Alabama 35660, United States
  • Research Center
    Bakersfield, California 93301, United States
  • Research Center
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Jul 2022, 4 months.

Results were first posted in Sep 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2022
First posted
Apr 7, 2022
StartActual
Feb 24, 2022
Primary completionActual
Jul 7, 2022
CompletionActual
Jul 7, 2022
Results first posted
Sep 13, 2023
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05315479
Lead sponsor
Baudax Bio
Responsible party
Sponsor
First posted
Apr 7, 2022
Start date
Feb 24, 2022
Primary completion
Jul 7, 2022
Completion
Jul 7, 2022
Results posted
Sep 13, 2023
Last update
Sep 13, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion